

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6344722

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SHAWN E.R. SCHILLER	06/28/2019
HONGBIN LI	12/12/2019
TORSTEN HERBERTZ	07/11/2019
BRADFORD GRAVES	07/03/2019
STEVEN MISCHKE	07/02/2019
ANNA ERICSSON	06/28/2019
JENNIFER R. DOWNING	07/08/2019
ANGELA V. WEST	07/03/2019
RECEIVING PARTY DATA	
Name:	FORMA THERAPEUTICS, INC.
Street Address:	500 ARSENAL STREET
City:	WATERTOWN
State/Country:	MASSACHUSETTS
Postal Code:	02472
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16946159
CORRESPONDENCE DATA	
Fax Number:	(801)817-9811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	801-817-9810
Email:	diana.martin@btlaw.com
Correspondent Name:	RYAN L. MARSHALL
Address Line 1:	BARNES & THORNBURG LLP
Address Line 2:	299 S. MAIN STREET, SUITE 1825
Address Line 4:	SALT LAKE CITY, UTAH 84111
ATTORNEY DOCKET NUMBER:	81829-317951
NAME OF SUBMITTER:	RYAN L. MARSHALL
SIGNATURE:	/Ryan L. Marshall/

PATENT

DATE SIGNED:	10/12/2020
Total Attachments: 13 source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page1.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page2.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page3.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page4.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page5.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page6.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page7.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page8.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page9.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page10.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page11.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page12.tif source=2020-10-10_81829-317951_Assignment_FOTH-054-03US#page13.tif	

ASSIGNMENT

WHEREAS, Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Ann Ericsson, and Jennifer R. Downing, the "Assignors", have made an invention entitled **INHIBITING CREB BINDING PROTEIN (CBP)**, for a full description of which reference is here made to applications identified in **Schedule A**;

WHEREAS, Forma Therapeutics, Inc., a corporation having a place of business at 500 Arsenal Street, Watertown, Massachusetts 02472, the "Assignee", desires to acquire the entire right, title and interest in the invention and the patent application identified above, and all patents which may be obtained for the invention, as set forth below;

NOW, THEREFORE, in consideration of valuable and legally sufficient consideration, the receipt of which by the Assignors from the Assignee is acknowledged, the Assignors have sold, assigned and transferred, and by these presents hereby sell, assign and transfer to the Assignee, the entire right, title and interest for the United States in the invention and the patent application identified above, and any patents that may issue for the invention in the United States; with the entire right, title and interest in the invention and all patent applications and patents issuing therefrom in all countries foreign to the United States, including the full right to claim for any such application all benefits and priority rights under any applicable convention; with the entire right, title and interest in all continuations, divisions, reissues, reexaminations, renewals and extensions of any of the patent applications and patents defined above; with the right to recover all damages, including, but not limited to, a reasonable royalty, by reason of past, present, or future infringement or any other violation of patent or patent application rights; to have hold for the sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignors covenant and agree, for both the Assignors and the Assignors' legal representatives, that the Assignors will assist the Assignee in the prosecution of the patent application identified above; in the making and prosecution of any other patent

applications that the Assignee may elect to make covering the invention identified above; in vesting in the Assignee exclusive title in all such other patent applications and patents; and that the Assignors will execute and deliver to the Assignee all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

The Commissioner of Patents and Trademarks is authorized and requested to issue patents to the Assignee under the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignors and Assignee have executed this agreement.

SCHEDULE A

Application Number	Application Date	Country
19183741.8	July 1, 2019	Europe
2019-123100	July 1, 2019	Japan
16/457,596	June 28, 2019	United States
PCT/US2019/039936	June 28, 2019	Patent Cooperation Treaty

Signature: 
Hongbin Li

Dated: 12/12/2019

Witness Signature: 

Witness Name (printed): PENG ZHAOYANG

Witness Signature: 

Witness Name (printed): He Pingwu

ASSIGNMENT

WHEREAS, Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Ann Ericsson, and Jennifer R. Downing, the "Assignors", have made an invention entitled **INHIBITING CREB BINDING PROTEIN (CBP)**, for a full description of which reference is here made to applications identified in **Schedule A**;

WHEREAS, Forma Therapeutics, Inc., a corporation organized and existing under the laws of the Commonwealth of Massachusetts, having a place of business at 500 Arsenal Street, Watertown, Massachusetts 02472, the "Assignee", desires to acquire the entire right, title and interest in the invention and the patent application identified above, and all patents which may be obtained for the invention, as set forth below;

NOW, THEREFORE, in consideration of valuable and legally sufficient consideration, the receipt of which by the Assignors from the Assignee is acknowledged, the Assignors have sold, assigned and transferred, and by these presents hereby sell, assign and transfer to the Assignee, the entire right, title and interest for the United States in the invention and the patent application identified above, and any patents that may issue for the invention in the United States; with the entire right, title and interest in the invention and all patent applications and patents issuing therefrom in all countries foreign to the United States, including the full right to claim for any such application all benefits and priority rights under any applicable convention; with the entire right, title and interest in all continuations, divisions, reissues, reexaminations, renewals and extensions of any of the patent applications and patents defined above; with the right to recover all damages, including, but not limited to, a reasonable royalty, by reason of past, present, or future infringement or any other violation of patent or patent application rights; to have hold for the sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignors covenant and agree, for both the Assignors and the Assignors' legal representatives, that the Assignors will assist the Assignee in the prosecution of the patent application identified above; in the making and prosecution of any other patent

applications that the Assignee may elect to make covering the invention identified above; in vesting in the Assignee exclusive title in all such other patent applications and patents; and that the Assignors will execute and deliver to the Assignee all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

The Commissioner of Patents and Trademarks is authorized and requested to issue patents to the Assignee under the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignors and Assignee have executed this agreement.

SCHEDULE A

Application Number	Application Date	Country
19183741.8	July 1, 2019	Europe
2019-123100	July 1, 2019	Japan
16/457,596	June 28, 2019	United States
PCT/US2019/039936	June 28, 2019	Patent Cooperation Treaty

Signature: Shawn E.R. Schiller
Shawn E.R. Schiller

Dated: 6-28-2019

Witness Signature: David Huang

Witness Name (printed): David Huang


Witness Signature: Betty Schiller

Witness Name (printed): Betty Schiller


FOTH-0054

Signature: 
Torsten Herbertz

Dated: 2019-07-11

Witness Signature: 

Witness Name (printed): XIAOPENG BAI

Witness Signature: 

Witness Name (printed): Casey Hermis

Signature: Bradford Graves
Bradford Graves

Dated: July 3, 2019

Witness Signature: Mary Graves

Witness Name (printed): Mary GRAVES

Witness Signature: Daniel Graves

Witness Name (printed): DANIEL GRAVES

Signature: Steven Mischke
Steven Mischke


Dated: 7-2-2019

Witness Signature: [Signature]


Witness Name (printed): Christopher Norris

Witness Signature: [Signature]

Witness Name (printed): Sylvie Maillet

Signature: 
Anna Ericsson

Dated: 06 28 19

Witness Signature: 

Witness Name (printed): Thomas R. LaSelle

Witness Signature: 

Witness Name (printed): Santos Diaz

Signature: 
Jennifer R. Downing

Dated: 7/8/2019

Witness Signature: 

Witness Name (printed): Ryan Abo

Witness Signature: 

Witness Name (printed): Tim Wigle

Signature: Angela V. West
Angela V. West

Dated: 2/3/19

Witness Signature: Rebecca J. Carazzo

Witness Name (printed): Rebecca J. Carazzo

Witness Signature: Yunyi Wei

Witness Name (printed): Yunyi Wei

The undersigned (whose title is supplied below) is authorized to act on behalf of
FORMA Therapeutics, Inc.

Signature: 

Date: 12/13/2019

Name (printed): Jeanette Potts

Title (printed): SVP, General Counsel